Navigation Links
New Book Highlights Human Cost of FDA's Failure to Investigate Medical Devices
Date:5/28/2009

NEW YORK, May 28 /PRNewswire-USNewswire/ -- A new history of shock treatment (electroconvulsive therapy, or ECT) - "Doctors of Deception: What They Don't Want You to Know About Shock Treatment" (Rutgers University Press) - reveals the human costs of the Food and Drug Administration's failure to investigate the devices that administer this controversial treatment for mental illnesses. The book is timely due to the FDA's recent decision to call on the manufacturers of the ECT device - and all high-risk Class III medical devices that were "grandfathered" in without the scientific testing that would be required today - to prove that it is safe and effective.

"The FDA has allowed shock machines to be used for 33 years without any evidence of their safety," said Linda Andre, the book's author and director of the Committee for Truth in Psychiatry, a national organization of former shock patients. Manufacturers of Class III devices may have to pay for costly clinical trials for devices that are already on the market, unless they can convince the FDA to change their classification to less risky, the Wall Street Journal reports. "If the manufacturers cannot provide such evidence, the agency is supposed to take the devices off the market," Andre said.

The FDA has known since 1979 that ECT poses serious risks, including brain damage and permanent memory loss. Andre's book chronicles the decades-long battle between former patients harmed by shock treatment and organized psychiatry over whether the shock machine should be investigated for safety, and includes first-person accounts from patients who were, Andre says, "guinea pigs for an untested device."

These patients formed their own organization to petition the FDA for brain-scan studies and for a consent form informing potential ECT patients of the known risks of ECT, and offered their own brains for study. They were joined by thousands of concerned citizens in a simple plea: If shock treatment is as safe as the American Psychiatric Association claims, why not investigate it?

In the past, bending to pressure from the APA, the FDA refused to conduct its own studies or require the manufacturers to prove safety. The agency said it would, instead, simply declare the device safe by reclassifying it as low risk (Class II).

"That is still the likeliest outcome," warns Andre.

Contact: Linda Andre, Committee for Truth in Psychiatry, 917-642-4625; ctip@rcn.com


'/>"/>
SOURCE Committee for Truth in Psychiatry
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Other highlights in the September 11 JNCI
4. NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue
5. Georgia Pecans Fit!: New Campaign Highlights Health Benefits, Recipes, Web Site
6. Highlights from the October 2007 Journal of the American Dietetic Association
7. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
8. NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue
9. Study Highlights Impact of Chronic Conditions on Working America
10. Report highlights inadequate pandemic planning as a threat to EU security
11. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... New York, NY (PRWEB) , ... May 23, 2016 , ... ... revolutionary, sport-injury preventative testing program for athletes. This is the first time this type ... South California, is being made available to the public in New York. , With ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... 23, 2016 , ... Hadley Institute for the Blind and ... blind or visually impaired, announces the election of Julie S. Tye as its ... Board of Trustees retained Morris & Berger, a firm specializing in non-profit executive ...
Breaking Medicine News(10 mins):
(Date:5/22/2016)... 23, 2016 DS Biopharma ... and anti-inflammatory compound DS102 in chronic obstructive pulmonary ... steatohepatitis (NASH) patients. Recent DS preclinical ... lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic ... The Company will publish further detail on these ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Oregon , May 19, 2016 ... titled, World Medical/Diagnostic Imaging Market -Opportunities and Forecasts, 2015 ... reach $45.0 billion by 2022, registering a CAGR of ... expected to continue to be the highest revenue-generating segment ... accounted for around one-third of the market share ...
Breaking Medicine Technology: